INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NuScale Power Corporation

UBS downgraded NuScale Power to Sell from Neutral and cut its price target to $6 from $10, citing an eroding SMR first-mover advantage, limited firm customer commitments, and an estimated $700 million of negative free cash flow over 2026-2028. NuScale shares fell $1.60, or 15.67%, to $8.61 on September 11. Pomerantz LLP is investigating potential securities-fraud and other claims related to the company and its officers and directors.

Analysis

The legal announcement is not independently informative on liability; the investable issue is whether SMR must fund a multi-year development gap before converting non-binding interest into bankable orders. A large cumulative cash burn would raise the probability of dilutive equity issuance, expensive project-level capital, or a strategic transaction—each likely compressing the premium multiple assigned to a perceived category leader. The near-term share reaction can extend as momentum holders reassess runway, but financing terms rather than litigation headlines are the key 1-3 month catalyst.

Competitive divergence within nuclear should widen rather than produce a sector-wide selloff. SMR’s execution slippage potentially benefits established nuclear equipment and services exposure such as BWXT and GEV, where revenue is tied more directly to funded government, utility, and defense programs; CEG also benefits if extended plant life and incremental conventional nuclear become the practical bridge while SMR deployment is delayed. A delayed Romanian project would additionally signal that overseas first-of-a-kind financing and sovereign support remain the bottleneck, reducing the value of international pipeline announcements across pre-revenue reactor developers.

The contrarian risk to a bearish SMR view is that strategic federal support, a TVA-related milestone, or an anchor customer with creditworthy financing can rapidly reprice the equity because the float is likely narrative-sensitive. The correct falsification test is not another memorandum of understanding: it is a binding contract with meaningful deposits, a funded construction schedule, or guidance showing cash use materially below the implied runway stress. Over 6-18 months, the thesis turns on cost of capital and project finance availability, not reactor-demand rhetoric.

Key Decisions for Investors

• Maintain a tactical short bias in SMR for the next 1-3 months only if borrow remains economical; target a move toward the revised $6 valuation framework (~30% downside from $8.61), with a hard risk review on any funded customer award or government financing commitment.
• Prefer a relative-value expression: long BWXT or GEV versus short SMR in equal beta-adjusted dollars over 3-6 months. This isolates the likely rotation from speculative reactor optionality into contracted nuclear supply-chain exposure; exit if SMR discloses binding, financed backlog rather than preliminary commercial interest.
• Do not trade the Pomerantz investigation itself. Treat it as a liquidity/sentiment accelerant and monitor for a formal complaint, adverse discovery, or insurance reserve disclosure; absent those, legal downside is secondary to financing dilution risk.
• Set an alert for the next cash-burn, liquidity, and share-count disclosure. If projected financing needs are addressed through a discounted equity raise or convertible issuance, press the short/relative-value trade; if liquidity is extended without material dilution, reduce exposure.